Stock Events

Stock Events

CERo Therapeutics 

$0.03
66
-$0-0.29% Wednesday 19:12

Statistics

Day High
0.04
Day Low
0.03
52W High
28.4
52W Low
0.03
Volume
260,341
Avg. Volume
528,408
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

3JunExpected
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Next
-124.26
-83.09
-41.92
-0.75
Expected EPS
-0.8004
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2021
2022
2023
2024
0Revenue
-21.03MNet Income

Analyst Ratings

$0.00Average Price Target
The highest estimate is 0.00.
From 2 ratings within the last 6 months. This is not an investment recommendation.
Buy
0%
Hold
100%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow CERO. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
CRISPR Therapeutics
CRSP
Mkt Cap5.82B
CRISPR Therapeutics focuses on gene editing technologies, similar to CERo Therapeutics' approach in genetic medicine.
Editas Medicine
EDIT
Mkt Cap276.95M
Editas Medicine works on genome editing using CRISPR, directly competing in the same innovative sector as CERo Therapeutics.
Intellia Therapeutics
NTLA
Mkt Cap1.35B
Intellia Therapeutics is another key player in the CRISPR technology space, making it a direct competitor in gene editing therapies.
Beam Therapeutics
BEAM
Mkt Cap2.53B
Beam Therapeutics also specializes in CRISPR technology, particularly base editing, a method that competes with CERo's gene editing approaches.
Sangamo Therapeutics
SGMO
Mkt Cap180.42M
Sangamo Therapeutics focuses on genomic medicine, including gene editing and gene therapy, areas that overlap with CERo's interests.
Allogene Therapeutics
ALLO
Mkt Cap275.13M
Allogene Therapeutics is involved in allogeneic CAR T-cell therapies, competing in the broader field of innovative cancer treatments like CERo.
Biomarin Pharmaceutical
BMRN
Mkt Cap10.29B
BioMarin Pharmaceutical develops gene therapies for genetic diseases, competing with CERo Therapeutics in the genetic medicine market.
Pfizer
PFE
Mkt Cap140.15B
Pfizer has a growing interest in gene therapy and biotechnology solutions for health issues, positioning it as a broader competitor.
Vertex Pharmaceuticals
VRTX
Mkt Cap109.11B
Vertex Pharmaceuticals engages in several areas including gene editing, making it a competitor in the innovative therapeutic sector.

About

CERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead program in hematologic malignancies targets an Eat Me signal upregulated on B cell and myeloid tumors. The company is based in South San Francisco, California.
Show more...
CEO
Mr. Christopher B. Ehrlich M.B.A.
Employees
8
Country
US
ISIN
US71902K4022

Listings

OTC Link
US
CERO
OTC Link
US
CEROW

0 Comments

Share your thoughts

FAQ

What is CERo Therapeutics stock price today?▼
The current price of CERO is $0.03 USD — it has decreased by -0.29% in the past 24 hours. Watch CERo Therapeutics stock price performance more closely on the chart.
What is CERo Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange CERo Therapeutics stocks are traded under the ticker CERO.
Is CERo Therapeutics stock price growing?▼
CERO stock has risen by +5.76% compared to the previous week, the month change is a -3.88% fall, over the last year CERo Therapeutics has showed a -99.76% decrease.
When is the next CERo Therapeutics earnings date?▼
CERo Therapeutics is going to release the next earnings report on June 03, 2026.
What were CERo Therapeutics earnings last quarter?▼
CERO earnings for the last quarter are -0.75 USD per share, whereas the estimation was -0.75 USD resulting in a +0% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is CERo Therapeutics revenue for the last year?▼
CERo Therapeutics revenue for the last year amounts to 0 USD.
What is CERo Therapeutics net income for the last year?▼
CERO net income for the last year is -21.03M USD.
How many employees does CERo Therapeutics have?▼
As of April 02, 2026, the company has 8 employees.
In which sector is CERo Therapeutics located?▼
CERo Therapeutics operates in the Health Care sector.
When did CERo Therapeutics complete a stock split?▼
The last stock split for CERo Therapeutics was on June 13, 2025 with a ratio of 1:20.
Where is CERo Therapeutics headquartered?▼
CERo Therapeutics is headquartered in South San Francisco, US.